ProQR Therapeutics BV (PRQR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.89 (+0.00%), Market cap $0.15B, 52-week low–high $1.37 ~ $3.05.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaborat
Financial statements, price targets, institutional (13F) holdings and related news for ProQR Therapeutics BV are updated in real time on BlackAll Trade.
ProQR Therapeutics BV trades at $1.89 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
ProQR Therapeutics BV has a market cap of about $0.15B.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiom